ACOTEC SCIENTIFIC HOLDINGS LIMITED Acotec Scientific Holdings Limited Stock
Equities
6669
KYG0096M1096
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.26 HKD | -3.40% |
|
-5.86% | -44.50% |
| Sales 2023 | 474M 65.4M 512M 89.4M | Sales 2024 * | 567M 78.31M 613M 107M | Capitalization | 1.82B 251M 1.96B 343M |
|---|---|---|---|---|---|
| Net income 2023 | 14M 1.93M 15.13M 2.64M | Net income 2024 * | 85M 11.73M 91.83M 16.04M | EV / Sales 2023 | 5.93 x |
| Net cash position 2023 | 404M 55.7M 436M 76.15M | Net cash position 2024 * | 453M 62.56M 490M 85.53M | EV / Sales 2024 * | 2.4 x |
| P/E ratio 2023 |
205
x | P/E ratio 2024 * |
20.7
x | Employees | 638 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 13.04% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.40% | ||
| 1 week | -5.86% | ||
| Current month | -20.15% | ||
| 1 month | -21.75% | ||
| 3 months | -24.58% | ||
| 6 months | -44.21% | ||
| Current year | -44.50% |
1 week
5.80
6.87
1 month
5.808.66
Current year
5.8011.46
1 year
5.8017.00
3 years
4.2119.88
5 years
4.2119.88
10 years
4.2119.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Li
CEO | Chief Executive Officer | 53 | 20-12-02 |
Weijia Li
CTO | Chief Tech/Sci/R&D Officer | 47 | 21-01-28 |
| Chief Operating Officer | 55 | 20-12-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Ni
BRD | Director/Board Member | 52 | 21-07-31 |
Kin Yee Poon
BRD | Director/Board Member | 52 | 21-01-28 |
Arthur Butcher
BRD | Director/Board Member | 53 | 23-02-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.26 | -3.40% | 286,000 |
| 24-04-25 | 6.48 | +4.01% | 304,000 |
| 24-04-24 | 6.23 | +2.13% | 301,378 |
| 24-04-23 | 6.1 | -2.87% | 284,000 |
| 24-04-22 | 6.28 | -5.56% | 330,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Acotec Scientific Holdings Ltd is a China-based interventional medical device company. The Company focuses on interventional treatment of vascular diseases, involving Drug-coated Balloons (DCB) and Percutaneous Transluminal Angioplasty Balloon Catheter (PTA) etc. The Company has established a product portfolio for five major therapeutic areas, including vascular surgery, cardiology, nephrology, neurology and andrology. The Company's business covers China, Asia, Europe and other countries and regions.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.795
CNY
Average target price
9.773
CNY
Spread / Average Target
+68.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.50% | 251M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.01B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- 6669 Stock
